低密度脂蛋白受体(LDLR)是急性髓系白血病独立的 adverse 预后因素
该研究分析187例强化治疗的急性髓系白血病(AML)患者骨髓活检中LDLR表达与生存的关系,发现LDLR表达升高与总生存、无事件生存降低及累积复发率升高相关,并在557例国际验证队列中确认,多因素回归分析含欧洲白血病网遗传风险分类后LDLR仍与结局相关。
要点
- LDLR表达升高与AML患者总生存、无事件生存降低及累积复发率升高相关。
- LDLR表达在包含欧洲白血病网遗传风险分类的多因素回归中仍与结局相关。
- 大多数健康组织中LDLR低表达,提示其可作为AML抗体药物递送靶点的潜力。
核心结论
- LDLR可预测AML患者结局,其预后价值超越现有风险因素。
- 大多数健康组织中LDLR低表达,提示其作为AML抗体药物递送靶点的潜力。
研究设计与样本
- 分析187例强化治疗的AML患者骨髓活检中LDLR表达与生存的关系,并在两个国际验证队列共557例强化治疗患者中验证。
主要发现
- LDLR表达升高与总生存降低相关:58·4%、44·2%、24·4%(P = 0·0018)。
- LDLR表达升高与无事件生存降低相关:41·7%、18·1%、14·3%(P = 0·0077)。
- LDLR表达升高与累积复发率升高相关:33·9%、55·1%、71·4%(P = 0·0011)。
- 在分析队列和验证队列中,包含欧洲白血病网遗传风险分类的多因素回归分析显示LDLR表达仍与结局相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The low-density lipoprotein receptor (LDLR) is a membrane receptor that mediates the endocytosis of low-density lipoprotein (LDL). Uptake of LDL has been proposed to contribute to chemotherapy resistance of acute myeloid leukaemia (AML) cell lines in vitro. In the present study, we analysed LDLR expression and survival using bone marrow biopsies from 187 intensively treated patients with AML. Here, increasing LDLR expression was associated with decreasing overall (58·4%, 44·2%, and 24·4%; P = 0·0018), as well as event-free survival (41·7%, 18·1%, and 14·3%; P = 0·0077), and an increasing cumulative incidence of relapse (33·9%, 55·1%, and 71·4%; P = 0·0011). Associations of LDLR expression with survival were confirmed in 557 intensively treated patients from two international validation cohorts. In the analytic and validation cohorts, LDLR expression remained associated with outcome in multivariable regression analyses including the European LeukemiaNet genetic risk classification. Thus, LDLR predicts outcome of patients with AML beyond existing risk factors. Furthermore, we found low expression levels of LDLR in most healthy tissues, suggesting it as a promising target for antibody-based pharmacodelivery approaches in AML.
引用
- Floeth M, Elges S, Gerss J, et al. Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia. Br J Haematol. 2020. PMID: 32511755. doi:10.1111/bjh.16853
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。